インフルエンザワクチン市場レポート：ワクチンタイプ、技術、年齢層、投与経路、地域別、2024～2032年

世界のインフルエンザワクチン市場規模は2023年に67億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに125億米ドルに達し、2024～2032年の間に6.9％の成長率（CAGR）を示すと予測しています。ワクチン接種プログラムを推進する政府機関による数々の有利なイニシアチブの開始、インフルエンザの流行と季節性アウトブレイクの増加、より効果的で幅広い予防効果を持つインフルエンザワクチンの採用は、世界市場を牽引する主要要因の一部です。

世界のインフルエンザワクチン市場分析

主要市場促進要因：インフルエンザワクチン市場の主要な市場促進要因の1つは、インフルエンザワクチン接種の重要性に関する一般市民の意識を高めるために医療機関が開始したイニシアティブの拡大です。これらの機関はまた、健康教育キャンペーンを実施しており、これが市場の成長を促進しています。さらに、各国の政府機関は、高齢者、医療従事者、小児などの優先年齢層に対して助成金や無料ワクチン接種を提供しており、これがワクチンへのアクセスを向上させています。

主要市場動向：インフルエンザワクチン市場の主要動向のひとつは、主要企業による4価ワクチンの製造・流通への投資の増加です。また、遺伝子組換えや細胞ベースのアプローチといった新技術の導入が、予測期間中のインフルエンザワクチン市場需要を押し上げると予想されます。

地理的動向：報告書によると、北米がインフルエンザワクチンの最大地域市場を占めています。ワクチン接種プログラムやキャンペーンを優先する医療当局の動きが活発化していることが、同地域市場を牽引しています。さらに、北米では医療インフラが整備されており、研究開発活動への投資が活発であることも、成長を促す大きな要因となっています。

競合情勢：インフルエンザワクチン市場における主要企業には、Abbott Laboratories、AstraZeneca plc、CSL Limited、第一三共株式会社、Emergent BioSolutions Inc.、F. Hoffmann-La Roche AG、Gamma Vaccines Pty Ltd、GlaxoSmithKline plc、Merck &Co.Inc.、Novartis AG、Pfizer Inc.、Sanofi、SINOVACなどがあります。

課題と機会：インフルエンザワクチン市場展望における主要課題のひとつは、ワクチンの流通に悪影響を与えかねない複雑な規制当局の承認プロセスです。これに加えて、生産規模を拡大し、さまざまな年齢層で有効性と安全性を確保する必要性が高まっていることが、世界市場をさらに阻害しています。しかし、インフルエンザワクチンが利用しやすく、効果的で、個人にも受け入れられるようにするための政府機関や公的医療機関の取り組みが活発化していることは、今後数年間のインフルエンザワクチン市場の成長を増大させ続けると考えられます。

世界のインフルエンザワクチン市場動向

季節性インフルエンザの流行とパンデミックの増加

季節性インフルエンザの増加により、入院率が上昇しています。例えば、2023年12月6日に発表されたStatista Researchのレポートによると、2022～2023年のインフルエンザシーズン中に米国で発生したインフルエンザ患者は3,100万人でした。さらに、2021～2022年のインフルエンザシーズン中にインフルエンザが原因で死亡した人の数は4,977人でした。これに加えて、米国では人口の大部分がワクチン接種を受けなかった。2021～2022年にかけて、インフルエンザの予防接種を受けたのは18歳から49歳のわずか37％で、幼児や高齢者に比べてはるかに低かった。そのため、インフルエンザ予防接種の重要性を強調する医療機関の注目が高まっており、市場の成長を後押ししています。例えば、2023年2月、世界保健機関（WHO）は、2023～2024年のインフルエンザシーズンに向けて、インフルエンザワクチンのウイルス構成に関する推奨事項を発表しました。この発表は、インフルエンザウイルスワクチンの組成に関する4日間の会議の最後に行われた説明会で行われました。

インフルエンザワクチン接種に対する意識の高まり

季節性インフルエンザの流行が拡大していることが、主に市場の成長を後押ししています。例えば、2022年2月に発表された世界のインフルエンザデータでは、世界で推定10億人が季節性インフルエンザに感染したと言及されています。これに伴い、この10億人のうち、毎年約300万人から500万人がインフルエンザの重症例に罹患しているとも記載されています。さらに、WHOが2022年12月に発表したデータによると、欧州では人口の5％～15％がインフルエンザに罹患していました。同様に、2021年7月に発表されたPlos One Journalの論文では、インフルエンザの新規感染症例の約5％～10％、20％～30％が毎年小児と成人の間で発生していると述べられています。インフルエンザウイルスの症例の増加は、インフルエンザワクチン接種に対する個人の意識を高めており、市場全体の成長に明るい展望をもたらしています。このほか、医療機関は予防接種の利点に関する情報を提供するキャンペーンを実施しており、これがインフルエンザワクチンの需要を促進しています。例えば、Sanofiが2022年6月に実施した医療調査では、薬剤師や医師が、65歳以上のインフルエンザ治療用に、Fluzone高用量4価ワクチンなどのワクチンを提供するよう米国疾病予防管理センター（CDC）に推奨したことが報告されています。あらゆる年齢層の個人における志向の高まりは、予測期間中、インフルエンザワクチン市場のシェアを押し上げ続けると考えられます。

政府機関による支援の高まり

世界中の政府機関が主要企業と協力して、インフルエンザワクチンの開発に関連する研究開発活動を支援しています。インフルエンザワクチン市場の統計によると、2021年9月、疾病対策予防センター（CDC）は、新型インフルエンザワクチンの高度開発を支援するBiomedical Advanced Research and Development Authority（BARDA）が調整する広範な省庁間パートナーシップを締結しました。さらに、政府当局は規制当局の承認プロセスを強化・緩和しており、これがインフルエンザワクチン市場の成長にプラスの影響を与えています。例えば、2022年7月、米国FDAはGlaxoSmithKlineの4価ワクチンであるFluarixの申請を承認しました。これに伴い、政府もインフルエンザ予防接種の開発に関連する臨床試験や研究開発活動に投資しています。例えば、2022年3月、オーストラリアの政府機関は、危険にさらされている人々を守るために、季節性インフルエンザワクチンに1億米ドル以上を投資しました。さらに、大手医療企業は、ワクチンという形で先進治療の導入に大規模な投資を行っています。このことが、インフルエンザワクチン市場の将来を後押ししています。

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
  • 一次情報
  • 二次情報
• 市場推定
  • ボトムアップアプローチ
  • トップダウンアプローチ
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

• 概要
• 主要業界動向

第5章 世界のインフルエンザワクチン市場

• 市場概要
• 市場実績
• COVID-19の影響
• 市場予測

第6章 市場内訳：ワクチンタイプ別

• 四価
• 三価

第7章 市場内訳：技術別

• 卵ベース
• 細胞ベース

第8章 市場内訳：年齢層別

• 小児
• 成人

第9章 市場内訳：投与経路別

• 注射
• 鼻スプレー

第10章 市場内訳：地域別

• 北米
  • 米国
  • カナダ
• アジア太平洋
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • インドネシア
  • その他
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • ロシア
  • その他
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • その他
• 中東・アフリカ
  • 市場動向
  • 市場内訳：国別
  • 市場予測

第11章 SWOT分析

• 概要
• 強み
• 弱み
• 機会
• 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

• 概要
• 買い手の交渉力
• 供給企業の交渉力
• 競合の程度
• 新規参入業者の脅威
• 代替品の脅威

第14章 価格分析

第15章 競合情勢

• 市場構造
• 主要企業
• 主要企業のプロファイル
  • Abbott Laboratories
  • AstraZeneca plc
  • CSL Limited
  • Daiichi Sankyo Company Limited
  • Emergent BioSolutions Inc.
  • F. Hoffmann-La Roche AG
  • Gamma Vaccines Pty Ltd
  • GlaxoSmithKline plc
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • SINOVAC

List of Figures

• Figure 1: Global: Influenza Vaccine Market: Major Drivers and Challenges
• Figure 2: Global: Influenza Vaccine Market: Sales Value (in Billion US$), 2018-2023
• Figure 3: Global: Influenza Vaccine Market Forecast: Sales Value (in Billion US$), 2024-2032
• Figure 4: Global: Influenza Vaccine Market: Breakup by Vaccine Type (in %), 2023
• Figure 5: Global: Influenza Vaccine Market: Breakup by Technology (in %), 2023
• Figure 6: Global: Influenza Vaccine Market: Breakup by Age Group (in %), 2023
• Figure 7: Global: Influenza Vaccine Market: Breakup by Route of Administration (in %), 2023
• Figure 8: Global: Influenza Vaccine Market: Breakup by Region (in %), 2023
• Figure 9: Global: Influenza Vaccine (Quadrivalent) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 10: Global: Influenza Vaccine (Quadrivalent) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 11: Global: Influenza Vaccine (Trivalent) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 12: Global: Influenza Vaccine (Trivalent) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 13: Global: Influenza Vaccine (Egg-based) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 14: Global: Influenza Vaccine (Egg-based) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 15: Global: Influenza Vaccine (Cell-based) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 16: Global: Influenza Vaccine (Cell-based) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 17: Global: Influenza Vaccine (Pediatric) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 18: Global: Influenza Vaccine (Pediatric) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 19: Global: Influenza Vaccine (Adult) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 20: Global: Influenza Vaccine (Adult) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 21: Global: Influenza Vaccine (Injection) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 22: Global: Influenza Vaccine (Injection) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 23: Global: Influenza Vaccine (Nasal Spray) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 24: Global: Influenza Vaccine (Nasal Spray) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 25: North America: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
• Figure 26: North America: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 27: United States: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
• Figure 28: United States: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 29: Canada: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
• Figure 30: Canada: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 31: Asia-Pacific: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
• Figure 32: Asia-Pacific: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 33: China: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
• Figure 34: China: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 35: Japan: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
• Figure 36: Japan: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 37: India: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
• Figure 38: India: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 39: South Korea: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
• Figure 40: South Korea: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 41: Australia: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
• Figure 42: Australia: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 43: Indonesia: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
• Figure 44: Indonesia: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 45: Others: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
• Figure 46: Others: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 47: Europe: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
• Figure 48: Europe: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 49: Germany: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
• Figure 50: Germany: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 51: France: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
• Figure 52: France: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 53: United Kingdom: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
• Figure 54: United Kingdom: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 55: Italy: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
• Figure 56: Italy: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 57: Spain: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
• Figure 58: Spain: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 59: Russia: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
• Figure 60: Russia: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 61: Others: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
• Figure 62: Others: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 63: Latin America: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
• Figure 64: Latin America: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 65: Brazil: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
• Figure 66: Brazil: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 67: Mexico: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
• Figure 68: Mexico: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 69: Others: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
• Figure 70: Others: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 71: Middle East and Africa: Influenza Vaccine Market: Sales Value (in Million US$), 2018 & 2023
• Figure 72: Middle East and Africa: Influenza Vaccine Market: Breakup by Country (in %), 2023
• Figure 73: Middle East and Africa: Influenza Vaccine Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 74: Global: Influenza Vaccine Industry: SWOT Analysis
• Figure 75: Global: Influenza Vaccine Industry: Value Chain Analysis
• Figure 76: Global: Influenza Vaccine Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Influenza Vaccine Market: Key Industry Highlights, 2023 and 2032
• Table 2: Global: Influenza Vaccine Market Forecast: Breakup by Vaccine Type (in Million US$), 2024-2032
• Table 3: Global: Influenza Vaccine Market Forecast: Breakup by Technology (in Million US$), 2024-2032
• Table 4: Global: Influenza Vaccine Market Forecast: Breakup by Age Group (in Million US$), 2024-2032
• Table 5: Global: Influenza Vaccine Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
• Table 6: Global: Influenza Vaccine Market Forecast: Breakup by Region (in Million US$), 2024-2032
• Table 7: Global: Influenza Vaccine Market: Competitive Structure
• Table 8: Global: Influenza Vaccine Market: Key Players

The global influenza vaccine market size reached US$ 6.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 12.5 Billion by 2032, exhibiting a growth rate (CAGR) of 6.9% during 2024-2032. The launch of numerous favorable initiatives by government bodies promoting vaccination programs, the rising prevalence of influenza and seasonal outbreaks, and the introduction of more effective and broadly protective influenza vaccines are some of the key factors driving the market globally.

Global Influenza Vaccine Market Analysis:

Major Market Drivers: One of the primary influenza vaccine market drivers is the growing initiatives launched by healthcare organizations to increase public awareness regarding the importance of influenza vaccinations. These agencies are also organizing health education campaigns, which are propelling the market growth. Furthermore, government bodies across countries are providing subsidies and free vaccinations for priority age groups, such as elderly individuals, healthcare workers, and children, which, in turn, is improving access to vaccines.

Key Market Trends: One of the primary influenza vaccine market trends is the rising investment by key players in the production and distribution of quadrivalent vaccines. In addition, the introduction of novel technologies, such as recombinant and cell-based approaches, is expected to bolster the influenza vaccine market demand over the forecasted period.

Geographical Trend: According to the report, North America holds the largest regional market for influenza vaccines. The increasing focus of healthcare authorities to prioritize vaccination programs and campaigns is driving the regional market. Furthermore, well-established healthcare infrastructures in North America and extensive investments in R&D activities are also acting as significant growth-inducing factors.

Competitive Landscape: Some of the prominent companies in the influenza vaccine market include Abbott Laboratories, AstraZeneca plc, CSL Limited, Daiichi Sankyo Company Limited, Emergent BioSolutions Inc., F. Hoffmann-La Roche AG, Gamma Vaccines Pty Ltd, GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi, and SINOVAC, among many others.

Challenges and Opportunities: One of the key challenges in the influenza vaccine market outlook is complex regulatory approval processes that can negatively impact the distribution of vaccines. In addition to this, the inflating need for scaling up production and ensuring efficacy and safety across various age groups is further hindering the global market. However, the rising efforts from government bodies and public healthcare organizations to ensure that influenza vaccines are accessible, effective, and accepted by individuals will continue to augment the influenza vaccine market growth in the coming years.

Global Influenza Vaccine Market Trends:

Increasing Seasonal Influenza Outbreaks and Pandemics

The rising cases of seasonal influenza are elevating the hospitalization rates. For example, according to the Statista Research report, published on December 6, 2023, there were 31 million cases of influenza in the United States during the 2022-2023 flu season. Moreover, there were 4,977 number of deaths caused by influenza during the 2021-2022 flu season. In addition to this, a large part of the population in the United States failed to get vaccinated. In 2021-2022, only 37 % of those aged 18 to 49 years received a flu vaccination, which was much lower as compared to children and the elderly. As such, the elevating focus among healthcare organizations on highlighting the importance of influenza vaccinations is bolstering the market growth. For instance, in February 2023, the World Health Organization (WHO) announced the recommendations for the viral composition of influenza vaccines for the 2023-2024 influenza season. The announcement was made at an information session at the end of a 4-day meeting on the composition of influenza virus vaccines.

The Rising Awareness Towards Influenza Vaccination

The growing prevalence of seasonal influenza is primarily bolstering the market growth. For example, the global flu data that was published in February 2022 mentioned that an estimated 1 billion individuals worldwide were infected by seasonal influenza. In line with this, the report also stated that out of those 1 billion, about 3 to 5 million people had a severe case of flu every year. Furthermore, according to the data published by WHO in December 2022, 5%-15% of the population was affected by influenza in the European region. Similarly, the Plos One Journal article published in July 2021 mentioned that approximately 5%-10% and 20%-30% of new cases of influenza infections occurred among children and adults annually. The elevating cases of the influenza virus are increasing awareness among individuals towards influenza vaccination, which is providing a positive outlook to the overall market growth. Besides this, healthcare organizations are launching campaigns to provide information regarding the benefits of immunization, thereby driving the demand for influenza vaccines. For example, a healthcare survey conducted in June 2022 by Sanofi reported that pharmacists and physicians recommended Centers for Disease Control and Prevention (CDC) to provide vaccines like Fluzone high-dose quadrivalent, for people who're 65 and older, for the treatment of influenza. The growing inclination among individuals of all age groups will continue to propel the influenza vaccine market share over the forecasted period.

The Growing Support from Government Bodies

Government bodies across the globe are collaborating with key companies to support R&D activities related to the development of influenza vaccines. As per the influenza vaccine market statistics, in September 2021, the Centers for Disease Control and Prevention (CDC) entered a broad inter-agency partnership coordinated by the Biomedical Advanced Research and Development Authority (BARDA) that supported the advanced development of novel influenza vaccines. Furthermore, government authorities are enhancing and easing the process of regulatory approvals, which is positively influencing the influenza vaccine market growth. For example, in July 2022, the United States FDA approved the request of GlaxoSmithKline for the Fluarix, which is a quadrivalent vaccine. In line with this, the government is also investing in clinical trials and R&D activities related to the development of influenza vaccinations. For instance, in March 2022, the government bodies in Australia invested more than US$ 100 Million in the seasonal influenza vaccine to protect individuals at risk. Additionally, major healthcare companies are investing extensively in the introduction of advanced therapy in the form of vaccines. This, in turn, is bolstering the future of influenza vaccine market.

Influenza Vaccine Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global influenza vaccine market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on vaccine type, technology, age group and route of administration.

Breakup by Vaccine Type:

Quadrivalent

Trivalent

Quadrivalent represents the most popular type of influenza vaccine

The report has provided a detailed breakup and analysis of the market based on the vaccine type. This includes quadrivalent and trivalent. According to the report, quadrivalent represented the largest segment.

Quadrivalent influenza vaccines are specifically designed to protect against four flu viruses, namely two influenza A viruses and two influenza B viruses. The quadrivalent segment holds a significant share of the influenza vaccine market, owing to its efficacy against viral infections, cost-effectiveness, and easy availability in clinics and hospitals. In addition to this, the fast product approvals for the quadrivalent type of vaccine are also fueling the market growth. For example, in July 2022, the United States FDA approved the request of GlaxoSmithKline for the Fluarix, which is a quadrivalent vaccine. The Fluarix quadrivalent vaccine provides active immunization to prevent disease caused by the influenza A subtype virus and type B virus. Furthermore, key companies are investing in vaccine facilities to elevate the production processes, thereby driving the global market for influenza vaccine. For example, in April 2021, Sanofi invested over € 600 million to build a new vaccine facility in Toronto to increase its supply of influenza vaccines in the United States, Canada, and Europe. The new facility developed quadrivalent influenza vaccines and served its customers with effective vaccinations.

Breakup by Technology:

Egg-based

Cell-based

Egg-based holds the largest share in the market

A detailed breakup and analysis of the market based on the technology has also been provided in the report. This includes egg-based and cell-based. According to the report, egg-based accounted for the largest market share.

Egg-based technology refers to one of the conventional methods utilized for vaccine production, wherein the influenza virus strains are grown in chicken eggs before being processed and harvested for vaccine formulation. Moreover, the egg-based method has been extensively adopted, owing to its established safety, scalability, cost-effectiveness, etc. For example, in February 2024, the WHO announced recommendations for the viral composition of influenza vaccines for the 2024-2025 influenza season in the northern hemisphere. The egg-based vaccines that are recommended include an A/Victoria/4897/2022 (H1N1)pdm09-like virus, an A/Thailand/8/2022 (H3N2)-like virus, and a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

Breakup by Age Group:

Pediatric

Adult

Pediatric dominates the market

A detailed breakup and analysis of the market based on the age group has also been provided in the report. This includes pediatric and adult. According to the report, pediatric accounted for the largest market share.

Pediatric vaccines are specifically formulated to enhance the immune systems of children, especially those under the age of five, who are more susceptible to severe flu-related complications. These vaccinations aid in ensuring adequate protection against the disease. Consequently, healthcare providers, government bodies, and parents are recognizing the importance of pediatric influenza vaccination, leading to the escalating demand for pediatric flu vaccines.

Breakup by Route of Administration:

Injection

Nasal Spray

A detailed breakup and analysis of the market based on the route of administration has also been provided in the report. This includes injection and nasal spray.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance in the market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest regional market for influenza vaccines.

In North America, the growing prevalence of the influenza virus is propelling the regional market. According to the CDC data, nearly 150,865 influenza-positive cases were reported in December 2022, among which 149,704 cases were influenza A and 1,61 influenza B virus types. In line with this, in December 2022, the Public Health Agency of Canada mentioned that nearly 34,413 influenza cases were reported in Canada from August 2022 to December 2022. Such increased occurrence of influenza cases among the population across North America is expected to drive the need for influenza vaccines. For instance, in June 2021, NIH launched the clinical trials of FluMos-v1, a vaccine candidate in the United States. This vaccine stimulates antibodies against multiple influenza virus strains by displaying part of the influenza virus proteins.

Competitive Landscape:

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the influenza vaccine top companies are listed below:

Abbott Laboratories

AstraZeneca plc

CSL Limited

Daiichi Sankyo Company Limited

Emergent BioSolutions Inc.

F. Hoffmann-La Roche AG

Gamma Vaccines Pty Ltd

GlaxoSmithKline plc

Merck & Co. Inc.

Novartis AG

Pfizer Inc.

Sanofi

SINOVAC

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Global Influenza Vaccine Market News:

March 2024: Osivax, a biopharmaceutical company, announced that all participants have completed their final visit in the Phase 2a clinical trial (NCT05734040) evaluating OVX836, which was a broad-spectrum influenza A vaccine and quadrivalent influenza vaccines (QIVs) candidate.

March 2024: Ahmedabad-based pharmaceutical company, Cadila Pharmaceuticals, announced the launch of a new influenza vaccine called Cadiflu Tetra.

February 2024: The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of two vaccines for active immunization against the H5N1 subtype of the influenza A virus, which causes avian influenza or bird flu.

October 2023: Mylab in Pune and Serum Institute of India have launched Nasovac S4, India's first needle-free nasal influenza vaccine.

Key Questions Answered in This Report

• 1. What was the size of the global influenza vaccine market in 2023?
• 2. What is the expected growth rate of the global influenza vaccine market during 2024-2032?
• 3. What are the key factors driving the global influenza vaccine market?
• 4. What are the key factors driving the global influenza vaccine market?
• 5. What has been the impact of COVID-19 on the global influenza vaccine market?
• 6. What is the breakup of the global influenza vaccine market based on the vaccine type?
• 7. What is the breakup of the global influenza vaccine market based on the technology?
• 8. What is the breakup of the global influenza vaccine market based on the age group?
• 9. What are the key regions in the global influenza vaccine market?
• 10. Who are the key players/companies in the global influenza vaccine market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Influenza Vaccine Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Vaccine Type

• 6.1 Quadrivalent
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Trivalent
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Technology

• 7.1 Egg-based
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Cell-based
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Age Group

• 8.1 Pediatric
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Adult
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by Route of Administration

• 9.1 Injection
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Nasal Spray
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Abbott Laboratories
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 AstraZeneca plc
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 CSL Limited
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
    • 15.3.3.4 SWOT Analysis
  • 15.3.4 Daiichi Sankyo Company Limited
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
    • 15.3.4.4 SWOT Analysis
  • 15.3.5 Emergent BioSolutions Inc.
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
    • 15.3.5.4 SWOT Analysis
  • 15.3.6 F. Hoffmann-La Roche AG
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 SWOT Analysis
  • 15.3.7 Gamma Vaccines Pty Ltd
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
  • 15.3.8 GlaxoSmithKline plc
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Merck & Co. Inc.
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 Novartis AG
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis
  • 15.3.11 Pfizer Inc.
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials
    • 15.3.11.4 SWOT Analysis
  • 15.3.12 Sanofi
    • 15.3.12.1 Company Overview
    • 15.3.12.2 Product Portfolio
    • 15.3.12.3 Financials
    • 15.3.12.4 SWOT Analysis
  • 15.3.13 SINOVAC
    • 15.3.13.1 Company Overview
    • 15.3.13.2 Product Portfolio
    • 15.3.13.3 Financials